艾可瑞妥單抗
| 单克隆抗体 | |
|---|---|
| 种类 | 双特异性T细胞接合器 |
| 目標 | CD3E, CD20 |
| 臨床資料 | |
| 商品名 | Epkinly, Tepkinly |
| 其他名稱 | GEN3013, epcoritamab-bysp |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623023 |
| 核准狀況 | |
| 给药途径 | 皮下注射 |
| 藥物類別 | 化学疗法 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 识别信息 | |
| CAS号 | 2134641-34-0 |
| DrugBank | |
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6471H9999N1735O2007S44 |
| 摩尔质量 | 145,624.95 g·mol−1 |
艾可瑞妥單抗（INN：Epcoritamab）是治疗弥漫大B细胞淋巴瘤的皮下注射藥品[7]。用於其它治療失效後的後線治療[7]。
常见的副作用包括细胞因子释放综合征、疲倦、肌肉骨骼疼痛、注射部位反应、发烧、腹痛、恶心和腹泻[7]。其他副作用包括可能感染和全血球減少症[7]。孕期使用可能對婴儿有害[7]。它是一种单克隆抗体，具双特异性CD20导向CD3 T細胞接合器[7]。
艾可瑞妥單抗于 2023 年在美国取得医疗使用許可[7]。
参考文獻
[编辑]- ^ Epkinly Product information. Health Canada. 22 October 2009 [3 March 2024].
- ^ Details for: Epkinly. Health Canada. 18 December 2023 [3 March 2024].
- ^ Summary Basis of Decision (SBD) for Epkinly. Drug and Health Products Portal. 1 September 2012 [9 May 2024].
- ^ Epcoritamab-bysp- epcoritamab injection, solution Epcoritamab-bysp- epcoritamab injection, solution, concentrate. DailyMed. 16 May 2023 [24 May 2023]. （原始内容存档于25 May 2023）.
- ^ Tepkinly Product information. Union Register of medicinal products. 25 September 2023 [1 October 2023].
- ^ Tepkinly EPAR. European Medicines Agency. 5 October 2023 [5 October 2023].
- ^ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 Epcoritamab-bysp- epcoritamab injection, solution Epcoritamab-bysp- epcoritamab injection, solution, concentrate. DailyMed. 16 May 2023 [24 May 2023]. （原始内容存档于25 May 2023）.
延伸閱讀
[编辑]- Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Journal of Clinical Oncology. April 2023, 41 (12): 2238–2247. PMC 10115554
. PMID 36548927. doi:10.1200/JCO.22.01725. - van der Horst HJ, de Jonge AV, Hiemstra IH, Gelderloos AT, Berry DR, Hijmering NJ, van Essen HF, de Jong D, Chamuleau ME, Zweegman S, Breij EC, Roemer MG, Mutis T. Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment. Blood Cancer Journal. February 2021, 11 (2): 38. PMC 7892878 . PMID 33602901. doi:10.1038/s41408-021-00430-6.
外部連結
[编辑]- Clinical trial number NCT03625037 for "First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE NHL-1)" at ClinicalTrials.gov
